Acute Kidney Injury Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Expected Acute Kidney Injury Market Size During the Forecast Period?
In recent times, the acute kidney injury market has seen significant expansion. The market which is estimated to be worth $5.37 billion in 2024 is projected to grow to $5.74 billion by 2025, showing a compound annual growth rate (CAGR) of 6.9%. Factors that have contributed to the growth during the historic period include the rising incidences of chronic diseases, an aging population, an increase in hospital-acquired infections, a heightened awareness about kidney health, and advancements in the field of critical care medicine.

The market size for acute kidney injury is forecasted to witness robust growth in the foroming years, expanding to $7.39 billion by 2029, with a compound annual growth rate (CAGR) of 6.5%. Several factors can account for this growth during the predicted period, including an increase in sepsis cases, a rising need for individualized treatment, larger government healare schemes, escalating healare spending in maturing markets, and a heightened emphasis on personalized healare and regenerative therapy. The expected trends during this market forecast period would be the adoption of wearable dialysis devices, application of artificial intelligence for optimizing treatments, utilization of compact renal replacement therapy systems, advances in continuous renal replacement therapy (CRRT), and inclusion of remote monitoring and telemedicine.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21079

What Are the High-Growth Segments in the Acute Kidney Injury Market?
The acute kidney injury market covered in this report is segmented -

1) By Injury: Pre-Renal Kidney Injury, Post-Renal Kidney Injury, Intrinsic Kidney Injury
2) By Treatment Type: Dialysis, Drug Therapy, Urinary Implants
3) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users

Subsegments:
1) By Pre-Renal Kidney Injury: Hypovolemia, Heart Failure-Related Injury, Sepsis-Induced Injury, Renal Artery Stenosis, Hepatorenal Syndrome
2) By Post-Renal Kidney Injury: Ureteral Obstruction, Bladder Outlet Obstruction, Prostate Enlargement (Benign Prostatic Hyperplasia), Kidney Stones, Tumors Affecting Urinary Tract
3) By Intrinsic Kidney Injury: Acute Tubular Necrosis (ATN), Acute Interstitial Nephritis (AIN), Glomerulonephritis, Vasculitis, Rhabdomyolysis-Induced Injury

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21079&type=smp

What Key Drivers Are Expected to Influence Future Acute Kidney Injury Market Growth?
The surge in diabetes cases is poised to fuel the expansion of the acute kidney injury market. Diabetes, a collective term representing a series of metabolic disorders marked by elevated blood sugar levels, arises either due to insufficient insulin production by the body or failure of cells to adequately respond to insulin. Factors such as increasing obesity percentages, unhealthy food habits, inactive lifestyles, aging populace, and strengthened awareness and diagnosis have spearheaded the rise in diabetes cases. Metabolic and inflammatory alterations triggered by acute kidney injury could potentially impact insulin resistance and glucose balance, revealing a convoluted interaction that might affect the trajectory and control of diabetes. For instance, the UK's Office for Health Improvement & Disparities reported in March 2024 that between March 2022 and March 2023, the proportion of individuals with type 1 diabetes complying with all the eight recommended care processes saw an uptick of 22%, and a 21% increase for type 2 diabetes. Moreover, the achievement rate of target HbA1c levels escalated to 37.9%, which is a record high as per the National Diabetes Audit (NDA). Hence, the escalating prevalence of diabetes contributes to the upward curve in the acute kidney injury market growth.

Which Companies Hold the Largest Share Across Different Acute Kidney Injury Market Segments?
Major companies operating in the acute kidney injury market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Medical Co. Ltd., Teva Pharmaceutical Industries Ltd., Baxter International Inc., B. Braun Melsungen AG, Nipro Corporation, Nikkiso Co. Ltd., Quark Pharmaceuticals Inc., Kringle Pharma Inc., Aptabio Therapeutics Inc., Alexion Pharmaceuticals Inc., Alloksys Life Sciences B.V., AM-Pharma B.V., Arch Biopartners Inc., Guard Therapeutics International AB

What Trends Are Driving Growth in The Acute Kidney Injury Market?
Key players in the acute kidney injury (AKI) market are strategically working towards securing regulatory approvals to expand their product offerings and introduce new treatment options. When we talk of regulatory approvals, it refers to permissions granted by official bodies like the FDA or EMA, which allow a product to be commercially distributed after it has been proven to be safe, effective, and of high quality. For instance, Mission Therapeutics Ltd., a biotechnology organization based in the UK, received FDA endorsement in December 2023 to kick-start a Phase II clinical trial for its foremost asset, MTX652, aimed at acute kidney injury (AKI) in high-risk patients following heart surgery. This trial is intended to target critical pathways associated with kidney injury and healing, with the goal of reducing inflammation, preventing additional kidney damage, and promoting recovery. This trial's distinctive aspect is its effort to use innovative therapeutic strategies to tackle the root molecular causes of AKI, which might present more efficient treatment alternatives compared to current interventions. The Phase II trial will assess MTX652's safety, effectiveness, and pharmacokinetics, providing vital data that could drive broader clinical use and possible approval.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/acute-kidney-injury-global-market-report

What Are the Emerging Geographies for The Acute Kidney Injury Market Growth?
North America was the largest region in the acute kidney injury market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute kidney injury market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Acute Kidney Injury Market?
2. What is the CAGR expected in the Acute Kidney Injury Market?
3. What Are the Key Innovations Transforming the Acute Kidney Injury Industry?
4. Which Region Is Leading the Acute Kidney Injury Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.